Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial
S. L. Aronson, Marta Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, Mignon D.J.M. van Gent, H. Arts, M. van Ham, Peter A. van Dam, Peter Vuylsteke, A. Aalbers, V. Verwaal, K. K. Van de Vijver, Neil K. Aaronson, G. Sonke, W. V. van Driel
{"title":"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial","authors":"S. L. Aronson, Marta Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, Mignon D.J.M. van Gent, H. Arts, M. van Ham, Peter A. van Dam, Peter Vuylsteke, A. Aalbers, V. Verwaal, K. K. Van de Vijver, Neil K. Aaronson, G. Sonke, W. V. van Driel","doi":"10.1097/01.ogx.0001008536.08634.9f","DOIUrl":null,"url":null,"abstract":"(Abstracted from Lancet Oncol 2023;24:P1109–P1118)\n Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.","PeriodicalId":509854,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"10 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0001008536.08634.9f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
(Abstracted from Lancet Oncol 2023;24:P1109–P1118)
Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
